Statin therapy in lupus-mediated atherogenesis: two birds with one stone?
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 21068103.
- Also identified by DOI 10.1136/ard.2010.133827 and PMC identifier 3306212.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The atherosclerotic process is accelerated in patients with systemic lupus erythematosus (SLE). In addition to a robust lipid-lowering effect, various immunomodulatory functions have been ascribed to statins. By virtue of the latter they may be able to reduce atherosclerotic vascular disease in SLE by inhibiting immune activation within the arterial wall and by attenuating lupus activity. The effects of statins on SLE as well as on lupus-mediated atherogenesis in vivo are discussed in this viewpoint.
Medical subject headings
- Atherosclerosis
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Lupus Erythematosus, Systemic